Total number of research projects/clinical trials funded by government, industries and non-governmental agencies during the last five years

2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
5	4	3	1	1

Year	Name of the Principle Investigator	Title of the project	Name of the Funding Agency	Document Link	
				Sanctioned	Utilization
2022-2023	Dr.Mettu Pradeep Reddy	Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the non-inferiority of immunogenicity and safety of single strain oral cholera vaccine HillcholÅ® (BBV131) to the comparator vaccine Shancholā.. along with lot-to-lot consistency of HillcholA® (BBV131)	Bharath Bio Tech	View Document	View Document
2022-2023	Dr.Mettu Pradeep Reddy	Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the non-inferiority of immunogenicity and safety of single strain oral cholera vaccine HillcholÅ® (BBV131) to the comparator vaccine Shancholā.. along with lot-to-lot consistency of HillcholA® (BBV131)	Bharath Bio Tech	View Document	View Document

2022-2023	Dr.B G Sankar	A Randomized, Assessor Blind, Active-Controlled, Multicenter, Parallel Group, Non-Inferiority Study to compare the Efficacy and Safety of GEN1501 (Insulin Glargine (r-DNA Origin) Injection 100 Units/mL) of GeneSys Biologics Pvt. Ltd., India with LANTUS® (Insulin Glargine (r-DNA Origin) Injection 100 Units/mL) in patients with Type 2 Diabetes Mellitus on Uncontrolled Oral Antidiabetic therapy (OAD).	GeneSys	View Document	View Document
2022-2023	Dr Kranthi Kumar	A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of Auxora in Patients with Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome(CRAPO)	Calcimedica	View Document	View Document
2022-2023	Dr.Giridhar Reddy B	A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome)	Zydus cadilla	View Document	View Document
2021-2022	Dr.Ajmera Prakash	A Prospective, Multicenter, Randomized, Comparative, Parallel Group Clinical Study to Compare The Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Intravenous Injection of Tenecteplase (Hetero Biopharma Limited) and Reference Medicinal Product (RMP-Tenecteplase, Boehringer Ingelheim) in Adults for the Thrombolytic Treatment of Suspected Myocardial Infarction with Persistent ST Elevation	Bio Pharma	View Document	View Document

2021-2022	Dr.Leelabati Toppo	A Phase 2 randomized, multi-centric, Clinical Trial of Heterologus Prime-Boost Combination of SARSCOV-2 Vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXINA®) with BBV154(Adenoviral Intranasal COVID-19 vaccine) in Healthy Volunteers.	Bharath Bio Tech	View Document	View Document
2021-2022	Dr. Subhash Reddy	A Multicentric, randomised, double blind, placebo controlled study to evaluate the safety & efficacy of Apremilast topical gel, 2%w/w in adult patients with mild to moderate plague psoriasis : Phase III clinical trial	Aizant	View Document	View Document
2021-2022	Dr.Leelabati Toppo	A Phase III randomized open label multi-center study to compare immunogenicity and safety of BBV154 with COVAXIN®, and to assess Lot to Lot Consistency of BBV154 in Healthy Volunteers. (BBIL/BBV154-III/2022)	Bharath Bio Tech	View Document	View Document
2020-2021	Dr.Archana Andhavarapu	A Phase III, Randomized,Controlled,Open-Label study to evaluate the efficacy and safety of Pegylated Interferon Alfa-2b in the treatment of adult patients diagnosed with SARS-Cov-2 (COVID-19)Protocol Number:PEGI.20.005	Zydus Cadilla	View Document	View Document
2020-2021	Dr. N Srinivas Rao	A phase III, randomized, multi-centre, double-blind, placebo-controlled study to evaluate efficacy, safety, and immunogenicity of Novel Corona Virus -2019-nCov	Zydus Cadilla	View Document	View Document

2020-2021	Dr. Ramprahlad K M	A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Sunitinib Malate Capsules 50mg of Eugia Pharma Specialities Limited (A Joint venture of Aurobindo Pharma Limited &Celon Laboratories Limited), India (Test) with Sutent® (Sunitinib Malate) capsules 50 mg of Pfizer Labs, USA (Reference) in adult patients with advanced renal cell carcinoma alreadyreceiving stable dose of Sunitinib Malate Capsules 50 mg under fasting conditions	Clinsync Clinical Reasearch	View Document	View Document
2019-2020	Dr.Ajmera Prakash	Ultra Thin strUt versus XiencE in a diabetic population with multi-Vessel Diseases -2- India study (TUXEDO - 2 INDIA)	Batra Hospital Medical Research	View Document	View Document
2018-2019	Dr. P. Kranthi Kumar	A Prospective, Multi-centre, Open label, Phase IV study to evaluate safety and efficacy profile of Infimab TM in patients with moderate to severe Crohns disease	Reliance Life Science	View Document	View Document

Institutional data in prescribed format: View Document

DVV Remark: HEI has not provided sanction letters, utilization certificate and audited statement

HEI Appeal: We are now submitting the missing sanction letters, utilization certificates, by the auditor.